AzTrials
AzTrials

Prediction ModelNCT05124587

Prediction for Critical Outcomes of Patients With COVID-19

An observational study of Prediction Model and COVID-19, run by Academic Centre for Dentistry in Amsterdam at 2 sites in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The study aims to develop and externally validate a prediction model for the critical outcomes of COVID-19 patients using predictors which can be easily obtained in clinical practice, including patients' demographic characteristics, self-reported medical conditions, and oral health. Read more about this study

Who is it for?
Ages 18 to 99 years
Conditions the study is for
Prediction Model, COVID-19, Oral Health
How many people
600 participants
Where
2 sitesNetherlands
Study dates
1 Sep 2021to Dec 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 99 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: The patients were diagnosed as COVID-19 from the Isala Hospital (Zwolle, the Netherlands) or from Noordwest Ziekenhuis (NWZ) (Alkmaar, the Netherlands).

Who may be able to join

  • patients who had a diagnosis of COVID-19 in the hospitals who visited the Department of Oral and Maxillofacial Surgery (OMFS) between March 2020 and May 2021, if they have had a dental panoramic radiograph (OPG), obtained up to a maximum of 5 years until the end of the current study.

Who cannot join

None listed.

Trial locations and contacts

2 sites in 1 country.

Netherlands2 sites
  • Noordwest Ziekenhuis (NWZ)

    Alkmaar

  • Isala Hospital

    Zwolle

Other trials in Netherlands

About this study

Official title: Development and External Validation of a Prediction Model for Critical Outcomes of Patients With Confirmed COVID-19 in the Hospital Setting Based on Demographic Characteristics, Medical Conditions and Oral Health

The study aims to develop and externally validate a prediction model for the critical outcomes of COVID-19 patients using predictors which can be easily obtained in clinical practice, including patients' demographic characteristics, self-reported medical conditions, and oral health.

Read the detailed description

Background The novel coronavirus disease 2019 (COVID-19) pandemic has presented an important and urgent threat to global health since its outbreak in December 2019. The COVID-19 does not only affect the respiratory tract, but also other organs in human body including lungs, liver, kidney, heart, vessels, and other organs (1). Respiratory failure and acute respiratory distress syndrome (ARDS) are the most common serious complications of COVID-19 infection (2). The crude mortality rates (CMRs) of COVID-19 varies in different locations, which ranges from 37.0/100,000 to 167.6/100,000 in several European countries up to 30th August 2020 (3). The in-hospital mortality of COVID-19 was reported to be 17.1% based on 33 studies from 13,398 patients (4), and it was 2.9 times higher than that of influenza based on the French national administrative database (5). It was reported that 26% of the COVID-19 patients admitted to ICU with severe status and 31% of the patients who admitted to ICU died based on 37 studies from 24,983 patients (6).

There are several risk factors on patients' demographic characteristics and underlying medical conditions which were shown be associated with the critical outcomes of COVID-19 (7). In addition, poor oral health, in particular periodontitis, was also shown to be associated with the critical outcomes of COVID-19 (8). Marouf et al. showed that COVID-19 patients with periodontitis had 8 times higher odds of death and 3.5 times higher odds of ICU admission than those without periodontitis based on a case-control study (9). This may be because periodontal disease could enhance cytokine release via altered microflora, expression of multiple viral receptors, bacterial superinfection, and aspiration of periodontal pathogens (10). The increased production of pro-inflammatory cytokine, which is referred to as cytokine storm, is the foremost cause of the adverse events of COVID-19 (10).

Because of the high contagiousness, high ICU admission rate, and high mortality of COVID-19, it has led to tremendous increases in the demand for hospital beds and shortage of medical equipment. Therefore, there is an urgent need for a pragmatic risk stratification tool that allows the early identification of the COVID-19 patients who are likely to be at highest risk of ICU admission and death (11). This can help clinicians and policymakers make the decisions on the management and optimize resource allocation. A recent review identified multiple prediction models which have been developed for prediction of prognosis of COVID-19 patients (12). Those prediction models varied in their predictors and performance of the models. A large number of prediction models reflected difficulties in their application in the rapid risk stratification for general COVID-19 patients at their first intake in hospitals because some predictors cannot be easily obtained without professional devices or lab tests, such as C reactive protein, peripheral oxygen saturation, and urea level. Many prediction models showed moderate performance in aspects of discrimination and calibration, and no benefit to clinical decision making (12). In addition, the dental variables were not considered the potential predictors in the previously developed models.

Therefore, the aim of the present study is to develop and externally validate a prediction model for the critical outcomes of COVID-19 patients using predictors which can be easily obtained in clinical practice, including patients' demographic characteristics, self-reported medical conditions, and oral health.

Materials and Methods Participants We include hospitalized patients and outpatients from the Isala Hospital (Zwolle, the Netherlands) with confirmed COVID-19 who visited the Department of Oral and Maxillofacial Surgery (OMFS) between March 2020 and May 2021, if they have had a dental panoramic radiograph (OPG), obtained up to a maximum of 5 years until the end of the current study. The patients are used to develop the prediction model (derivation cohort).

We also include the hospitalized patients and outpatients from Noordwest Ziekenhuis (NWZ) (Alkmaar, the Netherlands) with confirmed COVID-19 to externally validate the prediction model (validation cohort).

Potential predictors

The potential predictors include patients' demographic characteristics, self-reported medical conditions, and oral health. All the potential predictors are collected at baseline. The potential predictors are presented below:

Demographic characteristics

  • Gender
  • Age
  • BMI

Medical conditions

  • Smoking
  • Diabetes
  • Hypertension
  • Hypercholesterolemia
  • COPD
  • CVD
  • Chronic kidney disease
  • OSAS

Dental variables (based on OPG)

  • Number of teeth
  • Number of dental implants

Outcome (endpoint) The endpoint of the study is the presence or absence of the critical outcomes of COVID-19 (dichotomized). The course and outcome of the COVID-19 is classified into (1) ambulatory; (2) hospitalized; (3) ICU admission or death based on the WHO Clinical Progression Scale (13). In the study, the critical outcomes are defined as ICU admission or death, while the non-critical outcomes are defined that patients are ambulatory or hospitalized without ICU admission.

Statistical analysis The prediction modes will be developed and externally validated.

References

  1. Wang X, Fang X, Cai Z, et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research (Wash D C) 2020; 2402961.
  2. SeyedAlinaghi S, Afsahi AM, MohsseniPour M, et al. Late Complications of COVID-19; a Systematic Review of Current Evidence. Arch Acad Emerg Med 2021; 9: e14.
  3. Villani L, McKee M, Cascini F, et al. Comparison of deaths rates for COVID-19 across Europe during the first wave of the COVID-19 pandemic. Front Public Health 2020; 8: 620416.
  4. Macedo A, Gonçalves N, Febra C. COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis. Ann Epidemiol 2021; 57: 14-21.
  5. Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med 2021; 9: 251-259.
  6. Abate SM, Ali SA, Mantfardo B, et al. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One 2020; 15: e0235653.
  7. Kim HJ, Hwang H, Hong H, et al. A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic. Sci Rep 2021; 11: 9784.
  8. Botros N, Iyer P, Ojcius DM. Is there an association between oral health and severity of COVID-19 complications? Biomed J 2020; 43: 325-327.
  9. Marouf N, Cai W, Said KN, et al. Association between periodontitis and severity of COVID-19 infection: a case-control study. J Clin Periodontol 2021; 48: 483-491.
  10. Sukumar K, Tadepalli A. Nexus between COVID-19 and periodontal disease. J Int Med Res 2021; 49: 3000605211002695.
  11. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical characterization protocol: development and validation of the 4C mortality score. BMJ 2020; 370: m3339.
  12. Wynants L, Calster BV, Collins GS, et al. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. BMJ 2020; 369: m1328.
  13. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 2020; 20: e192-e197.
Being tested
No intervention group
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • No intervention groupOther

    No intervention group

Study groups in NCT05124587
Study groupRoleWhat they receive
Patients with confirmed COVID-19 in the hospital settingNot described
Receives: Other: No intervention group

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Critical outcomes of COVID-19

    The critical outcomes include death, and ICU admission

    Measured: March 2020 and May 2021

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Nov 2021
  2. Study start1 Sep 2021
  3. Primary completionDec 2021 (estimated)
  4. Study completionDec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
600 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05124587
Sponsor's protocol ID
2021.su
Status last verified
Nov 2021
First submitted
17 Nov 2021
Last updated
18 Nov 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Prediction Model and COVID-19, run by Academic Centre for Dentistry in Amsterdam at 2 sites in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 18 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Critical outcomes of COVID-19 (time frame: March 2020 and May 2021). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in